Immuron Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Immuron heeft een totaal eigen vermogen van A$12.7M en een totale schuld van A$0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk A$15.5M en A$2.8M.

Belangrijke informatie

Verhouding schuld/eigen vermogen

AU$0

Schuld

Rente dekkingsratio	n/a
Contant	AU$11.66m
Aandelen	AU$12.71m
Totaal verplichtingen	AU$2.84m
Totaal activa	AU$15.55m

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( A$14.7M ) IMC } overtreffen de korte termijn passiva ( A$2.7M ).

Langlopende schulden: De kortetermijnactiva IMC ( A$14.7M ) overtreffen de langetermijnschulden ( A$141.5K ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: IMC is schuldenvrij.

Schuld verminderen: IMC had 5 jaar geleden geen schulden.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: IMC heeft op basis van de huidige vrije kasstroom voldoende kasstroom voor meer dan een jaar.

Voorspelling contante baan: IMC heeft voldoende kasruimte voor 1.5 jaar als de vrije kasstroom blijft dalen met een historisch percentage van 9.9 % per jaar.

Immuron Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

Immuron Limited, Annual General Meeting, Nov 18, 2024

Immuron Limited Announces NMRC Reports Results for Campylobacter Clinical Study

Full year 2024 earnings released: AU$0.03 loss per share (vs AU$0.017 loss in FY 2023)

Full year 2024 earnings released: AU$0.03 loss per share (vs AU$0.017 loss in FY 2023)

Immuron Limited has filed a Follow-on Equity Offering in the amount of $2.069083 million.

Immuron Requests Pre-IND Meeting for IMM-529 with FDA Filing

Immuron Limited Appoints Jeannette Joughin as Director

Immuron Limited Announces Resignation of Roger Aston as Non-Executive Director

Immuron Limited Announces Positive Results Support Travelan Progress to Phase 3 Clinical Trials in the US

Immuron Limited Clinical Trials Update

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

Immuron Limited, Annual General Meeting, Nov 21, 2023

Immuron Limited Announces Travelan® Clinical Study Cohort 2 Commences

Full year 2023 earnings released: AU$0.017 loss per share (vs AU$0.013 loss in FY 2022)

Full year 2023 earnings released: AU$0.017 loss per share (vs AU$0.013 loss in FY 2022)

New major risk - Share price stability

Immuron Limited Announces First Patients Enrolled in Travelan® Clinical Study

Immuron Limited Initiates Recruitment of Travelan Clinical Study

Immuron Limited Announces US Food and Drug Administration Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves Way for Clinical Trial Initiation

First half 2023 earnings released: AU$0.009 loss per share (vs AU$0.008 loss in 1H 2022)

Immuron US DoD Naval Medical Research Center Responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic

Immuron Limited Receives FDA Approval for Travelan IND Application

Immuron Limited Submits IND Application To FDA for Travelan

Insufficient new directors

Immuron Limited, Annual General Meeting, Oct 28, 2022

Full year 2022 earnings released: AU$0.013 loss per share (vs AU$0.038 loss in FY 2021)

Immuron Limited Provides Update on IMM-124E SARS-CoV-2 Research

Insufficient new directors

Immuron Limited Provides Update on IND Application for Campylobacter ETEC Therapeutic

Immuron US DoD Naval Medical Research Center Submits IND Application for New Campylobacter ETEC Therapeutic

Immuron Limited Provides Update on the Planned Clinical Trial to Evaluate the Efficacy of Travelan and Two Third Party Non-Antibiotic Products in Travelers' Diarrhea

Immuron Limited Appoints Steven Lydeamore as Chief Executive Officer, effective June 27, 2022

Insufficient new directors

Immuron Limited Announces Work on the Investigational New Drug Application to Evaluate the Efficacy of A Single Dose Regimen of Travelan

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings released: AU$0.038 loss per share (vs AU$0.017 loss in FY 2020)

Executive Vice Chairman Peter Anastasiou has left the company

Insufficient new directors

Immuron Limited Provides Monash University Research Update on SARS-CoV-2 Program

First half 2021 earnings released: AU$0.026 loss per share (vs AU$0.009 loss in 1H 2020)

New 90-day low: AU$0.21

New 90-day low: AU$0.21

Immuron Limited Provides Update on Progress of the Anti-Viral Activity of IMM-124E

Immuron Limited Announces That the Naval Medical Research Center Has Completed the Characterisation of the Colostrum Harvested from Cows Immunized with the Experimental Vaccine Developed to Target Campylobacter and Enterotoxigenic E.Coli

Immuron Limited Announces US DoD NMRC Reports Positive Response to Vaccine

New 90-day low: AU$0.23

Immuron Limited Provides Shareholders and the Market with an Update on the Planned Clinical Programs in Travelers’ Diarrhea

Full year earnings released - AU$0.017 loss per share

Immuron Limited has completed a Follow-on Equity Offering in the amount of $20.000025 million.

New 90-day high - AU$0.87

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven